• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CABA

CABA

Cabaletta Bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.58

-0.10 (-2.72%)

Rating:C

Company Profile

CEO

Steven A. Nichtberger

IPO Date

2019-10-25

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.86

Prev. Close

$3.68

Day Low

$3.43

Day High

$3.93

52W Low

$1.26

52W High

$4.23

Market Cap

$0.58B

Volume

4.64M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

34.2%

Avg Negative

2.9%

Avg Neutral

63.1%

News Feed

Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder

Benzinga·8/18/2021·↑ positive

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

GlobeNewsWire·8/18/2021·↓ negative

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewsWire·8/5/2021·↑ positive

Cabaletta Bio to Present at the Jefferies Healthcare Conference

GlobeNewsWire·5/27/2021·↑ positive

Cabaletta Bio's Cell Therapy In Skin Blistering Disorder Shows Favorable Safety Profile

Benzinga·5/3/2021·↑ positive

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

GlobeNewsWire·5/3/2021·↓ negative

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

GlobeNewsWire·5/3/2021·↓ negative

Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

GlobeNewsWire·3/16/2021·↑ positive

Cabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young Biotech

Seeking Alpha·1/20/2021·↑ positive

Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris

GlobeNewsWire·12/8/2020·↑ positive